vorinostat has been researched along with Anterior Cerebral Circulation Infarction in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, Z | 1 |
| Zhang, Z | 1 |
| Zhang, Y | 1 |
| Wang, G | 1 |
| Huang, Z | 1 |
| Zhang, Q | 1 |
| Li, J | 1 |
1 other study available for vorinostat and Anterior Cerebral Circulation Infarction
| Article | Year |
|---|---|
Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
Topics: Animals; Brain Infarction; Dose-Response Relationship, Drug; Drug Design; Histone Deacetylase 6; His | 2021 |